Relay Therapeutics, Inc. (RLAY)
About Relay Therapeutics, Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $15.4M
- Net income
- -$276.5M
- Total assets
- $621.3M
- Market cap
- $2.9B
- Operating margin
- -1971.6%
- Net margin
- -1800.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $15.4M
- Operating expenses
- $318.1M
- Operating income
- -$302.7M
- Income tax
- $0
- Net income
- -$276.5M
- EPS (basic)
- $-1.61
- EPS (diluted)
- $-1.61
Balance sheet
- Total assets
- $621.3M
- Current assets
- $578.3M
- Total liabilities
- $54.3M
- Current liabilities
- $25.6M
- Shareholders’ equity
- $567.1M
Cash flow
- Operating cash flow
- -$235.5M
- Investing cash flow
- $192.8M
- Financing cash flow
- $1.6M
- Net cash flow
- -$41.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $2.9B
- EPS (diluted)
- $-1.61
- Shares outstanding
- 159.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 16, 2020
Relay Therapeutics, Inc. (RLAY) Stock Price
- Reported a net loss of $276.5M in FY2025.
- Revenue declined 49% from FY2021 to FY2025.
- Trading 11% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Relay Therapeutics, Inc..
Write a review
News about Relay Therapeutics, Inc.
News & sentiment via Polygon.io
Relay Therapeutics, Inc.: frequently asked questions
Is Relay Therapeutics, Inc. an American company?
Relay Therapeutics, Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Relay Therapeutics, Inc. headquartered?
Relay Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Relay Therapeutics, Inc. publicly traded?
Yes — Relay Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol RLAY on the NASDAQ.
What does Relay Therapeutics, Inc. do?
Relay Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
When was Relay Therapeutics, Inc. founded?
Relay Therapeutics, Inc. was founded in 2016.
